Bulk Pharmaceutical API Sources for MEXATE-AQ

Bulk Pharmaceutical API Sources for MEXATE-AQ

Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology		AC-7462
Molport		MolPort-006-118-727
AKos Consulting & Solutions		AKOS025311236
BOC Sciences		7413-34-5
Yuhao Chemical		JZ3127

Bulk Active Pharmaceutical Ingredient (API) Sources for MEXATE-AQ

Last updated: July 27, 2025

Introduction

MEXATE-AQ, known chemically as diatrizoate meglumine, is a widely used iodinated contrast agent primarily employed in diagnostic imaging procedures such as computed tomography (CT) scans and radiography. Its efficacy hinges on the purity and quality of its active pharmaceutical ingredient (API). Ensuring reliable, compliant, and cost-effective sourcing of the API is critical for manufacturers involved in producing MEXATE-AQ. This article analyzes the global landscape of bulk API suppliers, explores their capabilities, regulatory compliance, and strategic considerations vital for pharmaceutical companies sourcing diatrizoate meglumine.

---

Understanding MEXATE-AQ API

Diatrizoate meglumine belongs to the class of ionic, water-soluble contrast agents containing iodine. Its bulk API production demands rigorous process control to achieve high purity, traceability, and stability. The chemical synthesis involves multi-step processes with strict adherence to Good Manufacturing Practice (GMP) standards. Given the chemical complexity and regulatory scrutiny, sourcing an API from reputable suppliers becomes paramount.

---

Global API Suppliers for Diatrizoate Meglumine

1. Major International API Manufacturers

The most prominent suppliers of diatrizoate meglumine are well-established pharmaceutical manufacturers based in Europe, North America, and Asia. These firms demonstrate extensive GMP-certified facilities, robust quality assurance systems, and a history of regulatory compliance.

a. Cellmark (U.S.A.)

Cellmark, based in the United States, is among the leading API manufacturers specializing in contrast media components, including diatrizoate meglumine. Their API manufacturing facilities are FDA-inspected, with a comprehensive portfolio aligned with stringent U.S. Pharmacopeia (USP) standards. They emphasize quality control, ensuring APIs meet intense purity specifications suitable for injectable contrast agents.

b. Liebel-Flarsheim (U.S.A.)

Operating in the United States, Liebel-Flarsheim historically produces diagnostic imaging products and raw materials. Their API production facilities are GMP-compliant, offering high-quality diatrizoate meglumine with assured traceability. Their longstanding expertise in radiology contrast agents underpins their credibility in API sourcing.

c. Saint Gobain (France)

Saint Gobain, through its subsidiary, produces specialty chemicals, including components relevant to contrast media. The company’s extensive R&D facilities and adherence to European Medicines Agency (EMA) standards make its APIs reliable options for global pharmaceutical firms seeking high purity, regulatory compliance, and consistent supply.

d. Jiaxing HeYi Pharmaceutical (China)

China-based Jiaxing HeYi Pharmaceutical is recognized for bulk excipient and API manufacturing, including iodine-based contrast agents. Their GMP-certified facilities supply diatrizoate meglumine to international markets at competitive prices, with quality certifications aligning with USP and European Pharmacopoeia (Ph. Eur.).

2. Key Indian API Manufacturers

India’s booming pharmaceutical industry has increasingly become a hub for APIs, including contrast media components like diatrizoate meglumine.

a. Hetero Labs Ltd.

Hetero Laboratories Limited operates extensive API manufacturing facilities compliant with WHO-GMP standards. Their focus includes iodinated contrast agents, supporting global demand with reliable supply chains, competitive pricing, and adherence to regulatory norms.

b. Cadila Pharmaceuticals

Cadila Pharmaceuticals develops and supplies diatrizoate meglumine, emphasizing rigorous quality controls and regulatory filings within India and for export to the U.S., Europe, and other regions.

c. Sun Pharma Advanced Research Company (SPARC)

As part of Sun Pharma, SPARC involves in advanced R&D and manufacturing of APIs, including contrast media ingredients, leveraging cutting-edge technology platforms to ensure API quality and compliance.

3. Notable Asian API Suppliers

a. Beijing Biochemical Co., Ltd. (China)

This Chinese API manufacturer supplies diatrizoate meglumine to global markets, emphasizing cost efficiency, GMP compliance, and quality certified to international standards like USP and Ph. Eur.

b. Acebright Pharmaceuticals (India)

Acebright supplies a range of contrast media APIs, including diatrizoate meglumine. They maintain strict quality standards compatible with international regulatory bodies.

---

Regulatory Landscape and Certification

When selecting API sources, regulatory compliance is critical. Suppliers must hold certifications like GMP, ISO, and meet standards outlined by agencies such as the FDA, EMA, or the World Health Organization (WHO). Compliance with pharmacopoeial standards ensures API purity, stability, and safety, directly influencing the quality of MEXATE-AQ formulations.

Quality assurance attributes to consider include:

• Batch-to-batch consistency

• Validated manufacturing processes

• Analytical testing capabilities (e.g., HPLC, ICP-MS)

• Stability data

• Proper documentation and certification

---

Strategic Considerations in API Sourcing

1. Supply Chain Stability

Given the critical nature of contrast agents in diagnostics, a consistent and reliable supply chain is essential. Suppliers with diversified manufacturing plants and contingency plans mitigate risks related to geopolitical disruptions, raw material shortages, or regulatory hurdles.

2. Cost Efficiency Versus Quality

While price considerations are significant, they must not compromise quality. Suppliers with proven compliance and high-quality standards may require premium pricing but ensure product efficacy and reduce regulatory risks.

3. Regulatory Support

Manufacturers with established registration dossiers and experience in navigating complex regulatory submissions streamline the approval process for finished drug products containing diatrizoate meglumine.

4. Proprietary Technologies

Some suppliers utilize proprietary synthesis technologies that enhance API purity or reduce impurities, offering a competitive advantage and better performance in clinical applications.

---

Emerging Trends in API Sourcing

Recent trends focus on sustainable manufacturing practices, digitalization of quality control, and establishing regional API manufacturing hubs to meet increasing demand for contrast media solutions. Companies investing in robust quality management systems and strategic partnerships are better positioned to adapt to evolving regulatory landscapes while controlling costs.

---

Conclusion

The procurement of high-quality bulk API sources for MEXATE-AQ involves navigating a complex landscape of reputable manufacturers, regulatory requirements, and supply chain considerations. Leading suppliers across North America, Europe, and Asia, including Cellmark, Liebel-Flarsheim, Saint Gobain, Jiaxing HeYi Pharmaceutical, Hetero Labs, and Acebright Pharmaceuticals, offer reliable sourcing options. To ensure optimal product quality and compliance, pharmaceutical developers should prioritize GMP-certified suppliers with proven regulatory track records, diversified supply chains, and transparent quality assurance processes.

---

Key Takeaways

• Quality and compliance are paramount; prioritize GMP-certified API suppliers meeting international standards such as USP, Ph. Eur., or EMA.

• Regional manufacturing hubs in the U.S., Europe, and Asia offer diverse options balancing cost, quality, and supply stability.

• Strategic sourcing considers supply chain resilience, regulatory support, and technological capabilities.

• Emerging trends favor sustainable manufacturing practices and digital quality management, enhancing overall safety and efficiency.

• Due diligence involves thorough verification of supplier certifications, inspection reports, and quality assurance documentation.

---

FAQs

1. What are the most reliable regions to source diatrizoate meglumine API?
North America and Europe remain top regions due to stringent regulatory standards and established manufacturing practices. However, Asia, particularly India and China, has emerged as cost-effective sources with compliant facilities.

2. How does GMP certification influence API quality?
GMP certification ensures the manufacturing processes meet international quality standards, which is critical for APIs intended for injectable contrast agents like MEXATE-AQ, reducing risks of adverse reactions and regulatory rejection.

3. Can manufacturers switch API suppliers without regulatory issues?
Switching suppliers requires validation, stability studies, and regulatory updates. Early engagement with authorities and thorough documentation facilitate a seamless transition.

4. What role does the raw material iodine play in API quality?
Iodine quality directly impacts the purity and safety profile of diatrizoate meglumine. Suppliers sourcing high-purity iodine and controlling impurity profiles are crucial for API quality.

5. Are there sustainable or eco-friendly API manufacturing options?
Yes. Some suppliers are adopting green chemistry principles, reducing waste, utilizing renewable energy, and seeking certifications like ISO 14001 to promote sustainable practices.

---

References

1. U.S. Pharmacopeia [USP]. Diatrizoate Meglumine Monograph.
2. European Pharmacopoeia [Ph. Eur.]. Diatrizoate Meglumine Monograph.
3. Regulatory Compliance Reports, FDA and EMA databases.
4. Company websites and technical literature from Cellmark, Saint Gobain, Hetero Labs, Jiaxing HeYi, Acebright Pharmaceuticals.